Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

In clinical trials, Blujepa showed efficacy similar or superior to a leading existing UTI treatment, making it a valuable alternative. While Blujepa is generally well tolerated, the most common ...

In clinical trials, Blujepa showed efficacy similar or superior to a leading existing UTI treatment, making it a valuable alternative. While Blujepa is generally well tolerated, the most common ...

“The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific Officer, GSK. “We are proud to have developed ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics for the condition in nearly 30 years. Blujepa ...

The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be ...

Now, after nearly three decades without a novel oral antibiotic for UTIs, GlaxoSmithKline Pharmaceuticals' (GSK) newly approved drug, Blujepa (gepotidacin), offers hope. The need for a new UTI ...

Blujepa, the brand name for gepotidacin ... and half of all women experience a UTI in their lifetime, with some 30% of women suffering from recurrent episodes. “For many, UTIs can be a burden ...